Medibank Private Stock EBITDA
| MPL Stock | 3.78 0.02 0.53% |
Medibank Private fundamentals help investors to digest information that contributes to Medibank Private's financial success or failures. It also enables traders to predict the movement of Medibank Stock. The fundamental analysis module provides a way to measure Medibank Private's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medibank Private stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 813.6 M | 420.8 M |
Medibank | EBITDA |
Medibank Private Company EBITDA Analysis
Medibank Private's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Medibank Private EBITDA | 813.6 M |
Most of Medibank Private's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medibank Private is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Medibank Ebitda
Ebitda |
|
According to the company disclosure, Medibank Private reported earnings before interest,tax, depreciation and amortization of 813.6 M. This is 98.72% lower than that of the Insurance sector and significantly higher than that of the Financials industry. The ebitda for all Australia stocks is 79.13% higher than that of the company.
Medibank EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medibank Private's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medibank Private could also be used in its relative valuation, which is a method of valuing Medibank Private by comparing valuation metrics of similar companies.Medibank Private is currently under evaluation in ebitda category among its peers.
Medibank Private ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Medibank Private's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Medibank Private's managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Medibank Fundamentals
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.0005 % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 9.88 B | ||||
| Shares Outstanding | 2.75 B | ||||
| Shares Owned By Insiders | 0.12 % | ||||
| Shares Owned By Institutions | 42.21 % | ||||
| Price To Book | 4.49 X | ||||
| Price To Sales | 1.30 X | ||||
| Revenue | 8.02 B | ||||
| Gross Profit | 1.64 B | ||||
| EBITDA | 813.6 M | ||||
| Net Income | 3.9 M | ||||
| Cash And Equivalents | 420.6 M | ||||
| Total Debt | 218.3 M | ||||
| Book Value Per Share | 0.84 X | ||||
| Cash Flow From Operations | 868.5 M | ||||
| Earnings Per Share | 0.18 X | ||||
| Target Price | 4.08 | ||||
| Number Of Employees | 3.22 K | ||||
| Beta | 0.2 | ||||
| Market Capitalization | 10.41 B | ||||
| Total Asset | 4.69 B | ||||
| Retained Earnings | 2.07 B | ||||
| Annual Yield | 0.04 % | ||||
| Net Asset | 4.69 B | ||||
| Last Dividend Paid | 0.17 |
About Medibank Private Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medibank Private's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medibank Private using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medibank Private based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Medibank Stock Analysis
When running Medibank Private's price analysis, check to measure Medibank Private's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medibank Private is operating at the current time. Most of Medibank Private's value examination focuses on studying past and present price action to predict the probability of Medibank Private's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medibank Private's price. Additionally, you may evaluate how the addition of Medibank Private to your portfolios can decrease your overall portfolio volatility.